amlodipine has been researched along with Proteinuria in 67 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chlorthalidone is a very effective antihypertensive drug, but it has not been studied prospectively in kidney transplant recipients with hypertension." | 9.24 | Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. ( Hesselink, DA; Hoorn, EJ; Moes, AD; van den Meiracker, AH; Zietse, R, 2017) |
| "Twelve weeks of treatment with losartan significantly reduced proteinuria compared with placebo/amlodipine: losartan -14." | 9.15 | Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial. ( Gleim, GW; Lam, C; Le Bailly De Tilleghem, C; Shahinfar, S; Strehlau, J; Webb, NJ; Wells, TG, 2011) |
| "We examined the effects of 2 calcium channel blockers, benidipine (T-, L-, and N-type) and amlodipine (L- and N-type), on renal, inflammatory, oxidative, and atherosclerosis markers in hypertensive patients with mild chronic kidney disease (CKD)." | 9.14 | Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease. ( Fujiwara, N; Kawagoe, Y; Koide, H; Nakamura, T; Sato, E; Sugaya, T; Ueda, Y; Yamada, S; Yamagishi, S, 2010) |
| "Losartan significantly lowered proteinuria and was well tolerated after 12 weeks in children aged 1 to 17 years with proteinuria with or without hypertension, a population that has not previously been rigorously studied." | 9.14 | Randomized, double-blind, controlled study of losartan in children with proteinuria. ( Gleim, GW; Lam, C; Loeys, T; Manas, D; Santoro, E; Shahinfar, S; Strehlau, J; Webb, NJ; Wells, TG, 2010) |
| "In addition to reducing urinary protein excretion, losartan at 100 mg daily increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetic nephropathy." | 9.12 | Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. ( Jin, HM; Pan, Y, 2007) |
| " The present study compared the chronic effects of efonidipine and amlodipine on proteinuria in patients with chronic glomerulonephritis." | 9.12 | Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. ( Akashiba, A; Ishimitsu, T; Kameda, T; Matsuoka, H; Minami, J; Numabe, A; Ohta, S; Ono, H; Takahashi, T; Yoshii, M, 2007) |
| " This study compared cilnidipine and amlodipine with respect to their effects on renal function and proteinuria." | 9.11 | Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. ( Kojima, S; Shida, M; Yokoyama, H, 2004) |
| " The aim of the present study was to compare the effects of losartan and amlodipine on proteinuria, as well as on serum and urine TGF-beta1 levels in IgA nephropathy patients with hypertension and proteinuria." | 9.10 | Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy. ( Choi, KH; Choi, S; Goo, YS; Ha, SK; Han, DS; Kang, SW; Lee, HY; Park, HC; Xu, ZG, 2003) |
| "Ramipril, compared with amlodipine, retards renal disease progression in patients with hypertensive renal disease and proteinuria and may offer benefit to patients without proteinuria." | 9.09 | Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. ( Agodoa, LY; Appel, L; Bakris, GL; Beck, G; Bourgoignie, J; Briggs, JP; Charleston, J; Cheek, D; Cleveland, W; Douglas, JG; Douglas, M; Dowie, D; Faulkner, M; Gabriel, A; Gassman, J; Greene, T; Hall, Y; Hebert, L; Hiremath, L; Jamerson, K; Johnson, CJ; Kopple, J; Kusek, J; Lash, J; Lea, J; Lewis, JB; Lipkowitz, M; Massry, S; Middleton, J; Miller, ER; Norris, K; O'Connor, D; Ojo, A; Phillips, RA; Pogue, V; Rahman, M; Randall, OS; Rostand, S; Schulman, G; Smith, W; Thornley-Brown, D; Tisher, CC; Toto, RD; Wright, JT; Xu, S, 2001) |
| " Supportive medical therapy was carried out and persistent systemic hypertension was managed using telmisartan." | 7.88 | Successful management of proteinuria and systemic hypertension in a dog with renal cell carcinoma with surgery, telmisartan, and amlodipine. ( Kang, SS; Kim, HJ; Kwon, YJ; Suh, GH, 2018) |
| "Clinical studies have indicated the beneficial effect of an L/N-type calcium channel blocker (CCB), cilnidipine, on the progression of proteinuria in hypertensive patients compared with an L-type CCB, amlodipine." | 7.76 | Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte. ( Asanuma, K; Fan, YY; Fujita, T; Hitomi, H; Kobori, H; Kohno, M; Nakano, D; Nishiyama, A; Noma, T; Ohashi, N; Ohsaki, H; Suwarni, D; Tomino, Y, 2010) |
| "Eighty subjects with type 2 diabetic nephropathy were randomly divided into two groups: losarten group (n = 41) and amlodipine group (n = 39)." | 6.74 | Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009) |
| "Compared with the placebo-treated group, proteinuria was significantly lower in the irbesartan- and efonidipine-treated groups, but not in the amlodipine-treated group." | 5.36 | Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats. ( Jin, D; Miyazaki, M; Sakonjo, H; Takai, S, 2010) |
| "Chlorthalidone is a very effective antihypertensive drug, but it has not been studied prospectively in kidney transplant recipients with hypertension." | 5.24 | Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. ( Hesselink, DA; Hoorn, EJ; Moes, AD; van den Meiracker, AH; Zietse, R, 2017) |
| "Ramipril attenuates renal Fibroblast growth factor-23 (FGF-23) expression, ameliorates proteinuria and normalizes serum phosphate in the diabetic Zucker rat with progressive renal disease suggesting that the renoprotective effect by this drug may be in part due to a FGF-23-lowering effect of angiotensin-converting enzyme (ACE) inhibition." | 5.19 | Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy. ( Cetinkaya, H; Eyileten, T; Gok, M; Karaman, M; Kurt, YG; Mallamaci, F; Oguz, Y; Saglam, M; Sonmez, A; Unal, HU; Vural, A; Yilmaz, MI; Zoccali, C, 2014) |
| "Twelve weeks of treatment with losartan significantly reduced proteinuria compared with placebo/amlodipine: losartan -14." | 5.15 | Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial. ( Gleim, GW; Lam, C; Le Bailly De Tilleghem, C; Shahinfar, S; Strehlau, J; Webb, NJ; Wells, TG, 2011) |
| "Losartan significantly lowered proteinuria and was well tolerated after 12 weeks in children aged 1 to 17 years with proteinuria with or without hypertension, a population that has not previously been rigorously studied." | 5.14 | Randomized, double-blind, controlled study of losartan in children with proteinuria. ( Gleim, GW; Lam, C; Loeys, T; Manas, D; Santoro, E; Shahinfar, S; Strehlau, J; Webb, NJ; Wells, TG, 2010) |
| "We examined the effects of 2 calcium channel blockers, benidipine (T-, L-, and N-type) and amlodipine (L- and N-type), on renal, inflammatory, oxidative, and atherosclerosis markers in hypertensive patients with mild chronic kidney disease (CKD)." | 5.14 | Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease. ( Fujiwara, N; Kawagoe, Y; Koide, H; Nakamura, T; Sato, E; Sugaya, T; Ueda, Y; Yamada, S; Yamagishi, S, 2010) |
| " We hypothesized that a trandolapril/verapamil SR (T/V) fixed-dose combination (FDC) was superior to a benazepril/amlodipine (B/A) FDC for reducing albuminuria in 304 hypertensive diabetic nephropathy patients when treated for 36 weeks." | 5.13 | Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy. ( Bacher, P; Champion, A; Fakouhi, K; Tian, M; Toto, RD, 2008) |
| "In addition to reducing urinary protein excretion, losartan at 100 mg daily increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetic nephropathy." | 5.12 | Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. ( Jin, HM; Pan, Y, 2007) |
| " The present study compared the chronic effects of efonidipine and amlodipine on proteinuria in patients with chronic glomerulonephritis." | 5.12 | Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. ( Akashiba, A; Ishimitsu, T; Kameda, T; Matsuoka, H; Minami, J; Numabe, A; Ohta, S; Ono, H; Takahashi, T; Yoshii, M, 2007) |
| "The African American Study of Kidney Disease and Hypertension examined the effect on renal function decline of 2 blood pressure (BP) goals (low mean arterial pressure [MAP] < or =92 versus usual MAP 102 to 107 mm Hg) and 3 antihypertensives (ramipril versus amlodipine versus metoprolol)." | 5.11 | Blood pressure control, drug therapy, and kidney disease. ( Agodoa, LY; Cheek, D; Contreras, G; Dowie, D; Greene, T; Junco, G; Lash, J; Lipkowitz, M; Miller, ER; Ojo, A; Sika, M; Toto, RD; Wilkening, B, 2005) |
| "Associations between baseline proteinuria and proteinuria reduction by either irbesartan, amlodipine, or control for similar decrements in blood pressure and the cumulative incidence of renal end points were examined using the Kaplan-Meier method in patients enrolled in the Irbesartan Diabetic Nephropathy Trial." | 5.11 | Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. ( Atkins, RC; Braden, G; Briganti, EM; Champion de Crespigny, PJ; DeFerrari, G; Drury, P; Hunsicker, LG; Lewis, EJ; Lewis, JB; Locatelli, F; Wiegmann, TB, 2005) |
| "The renoprotective effect of candesartan is considered more favorable than amlodipine in the treatment of ADPKD." | 5.11 | Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. ( Higaki, Y; Higashihara, E; Horie, S; Hosoya, T; Kamura, K; Mochizuki, T; Nakayama, T; Nutahara, K; Shimizu, T; Tsuchiya, K; Yamamoto, N, 2005) |
| " This study compared cilnidipine and amlodipine with respect to their effects on renal function and proteinuria." | 5.11 | Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. ( Kojima, S; Shida, M; Yokoyama, H, 2004) |
| "Losartan induced a drastic decrease in proteinuria accompanied by a reduction in urinary excretion of TGF-beta in patients with non-diabetic proteinuric renal diseases." | 5.10 | Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. ( Aguirre, R; Andrade, CF; Ara, JM; Arias, M; Bernis, C; Campistol, JM; Galceran, JM; Luño, J; Marín, R; Mora, J; Poveda, R; Praga, M; Prat, MV; Rivera, F, 2003) |
| "We tested whether the combination of verapamil (V) or amlodipine (A) with trandolapril (T) affected proteinuria differently from T alone in patients with nondiabetic nephropathies." | 5.10 | The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study. ( Berto, IM; Boero, R; Lanfranco, G; Massara, C; Perosa, P; Quarello, F; Rollino, C; Vagelli, G, 2003) |
| " The aim of the present study was to compare the effects of losartan and amlodipine on proteinuria, as well as on serum and urine TGF-beta1 levels in IgA nephropathy patients with hypertension and proteinuria." | 5.10 | Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy. ( Choi, KH; Choi, S; Goo, YS; Ha, SK; Han, DS; Kang, SW; Lee, HY; Park, HC; Xu, ZG, 2003) |
| "Ramipril, compared with amlodipine, retards renal disease progression in patients with hypertensive renal disease and proteinuria and may offer benefit to patients without proteinuria." | 5.09 | Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. ( Agodoa, LY; Appel, L; Bakris, GL; Beck, G; Bourgoignie, J; Briggs, JP; Charleston, J; Cheek, D; Cleveland, W; Douglas, JG; Douglas, M; Dowie, D; Faulkner, M; Gabriel, A; Gassman, J; Greene, T; Hall, Y; Hebert, L; Hiremath, L; Jamerson, K; Johnson, CJ; Kopple, J; Kusek, J; Lash, J; Lea, J; Lewis, JB; Lipkowitz, M; Massry, S; Middleton, J; Miller, ER; Norris, K; O'Connor, D; Ojo, A; Phillips, RA; Pogue, V; Rahman, M; Randall, OS; Rostand, S; Schulman, G; Smith, W; Thornley-Brown, D; Tisher, CC; Toto, RD; Wright, JT; Xu, S, 2001) |
| "The objective of this study was to examine the effects of angiotensin II receptor blocker losartan versus the calcium channel blocker amlodipine on proteinuria, renal haemodynamics, glomerular sieving and tubular function in hypertensive patients with non-diabetic nephropathy." | 5.08 | Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. ( Berg, KJ; Fauchald, P; Hartmann, A; Holdaas, H; Lund, K, 1998) |
| "Currently, AIIAs such as losartan represent the only evidence-based treatment strategy for patients with type 2 DM and proteinuria." | 4.82 | Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. ( Ruilope, LM; Segura, J, 2003) |
| "SEVERAL MECHANISMS: The progression in renal failure first implies hemodynamic mechanisms and among which angiotensin II has a central role, but also an increase in proteinuria and the induction of many inflammatory and mitogenic mediators that enhance fibrosis (TGF-beta), an effect stimulating the thrombotic mechanism." | 4.81 | [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. ( Bernadet-Monrozies, P; Durand, D; Kamar, N; Rostaing, L, 2002) |
| " Supportive medical therapy was carried out and persistent systemic hypertension was managed using telmisartan." | 3.88 | Successful management of proteinuria and systemic hypertension in a dog with renal cell carcinoma with surgery, telmisartan, and amlodipine. ( Kang, SS; Kim, HJ; Kwon, YJ; Suh, GH, 2018) |
| " The PARTNER (Practical combination therapy of Amlodin and angiotensin II Receptor blocker; Safety and efficacy in paTieNts with hypERtension) study is a prospective specific clinical use survey examining the efficacy and safety of 12-week treatment with amlodipine (AML) and Angiotensin II Receptor Blocker (ARB) in 5900 hypertensive patients." | 3.81 | The therapeutic advantage of combination antihypertensive drug therapy using amlodipine and irbesartan in hypertensive patients: Analysis of the post-marketing survey data from PARTNER (Practical combination therapy of Amlodin and angiotensin II Receptor ( Fukuda, H; Ishibashi, K; Ishimitsu, T; Nagao, M; Nukui, K; Sato, F; Uchida, M, 2015) |
| "The results of this study suggested that the L/N-type CCB, cilnidipine, had additive antihypertensive and proteinuria-lowering effects when administered in combination with an ARB, even in type-1 diabetic rats, and that the L-type CCB, amlodipine, did not." | 3.79 | Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats. ( Aritomi, S; Konda, T; Niinuma, K; Nitta, K; Ogawa, T, 2013) |
| "Clinical studies have indicated the beneficial effect of an L/N-type calcium channel blocker (CCB), cilnidipine, on the progression of proteinuria in hypertensive patients compared with an L-type CCB, amlodipine." | 3.76 | Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte. ( Asanuma, K; Fan, YY; Fujita, T; Hitomi, H; Kobori, H; Kohno, M; Nakano, D; Nishiyama, A; Noma, T; Ohashi, N; Ohsaki, H; Suwarni, D; Tomino, Y, 2010) |
| "Our data show that the effects of losartan and amlodipine on the absolute mean reduction of blood pressure and proteinuria in non-diabetic nephropathy patients are similar between the different ACE or AGT genotypes." | 3.73 | [Pharmacogenetics of angiotensin system in non diabetic nephropathy]. ( Alvarez, V; Arias, M; Campistol, JM; Coto, E; Fernández Andrade, C; Galcerán, JM; Luño, J; Marín, R; Poveda, R; Praga, M; Rivera, F; Vallés, M, 2005) |
| "Proteinuria was positively correlated with circulating AGE and sRAGE levels in our subjects." | 2.76 | Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease. ( Fujiwara, N; Kawagoe, Y; Koide, H; Nakamura, T; Sato, E; Takeuchi, M; Ueda, Y; Yamagishi, S, 2011) |
| "Proteinuria was evaluated by 24-h home urine collection for all patients." | 2.75 | Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors - a multicenter, open, randomized trial using 24-hour urine collection. ( Kawano, Y; Matsuoka, H; Miwa, Y; Ohta, Y; Sasaguri, T; Tominaga, M; Tsuchihashi, T; Ueno, M, 2010) |
| "Eighty subjects with type 2 diabetic nephropathy were randomly divided into two groups: losarten group (n = 41) and amlodipine group (n = 39)." | 2.74 | Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009) |
| "Losartan was administered once daily at doses of 25 to 100 mg/day, and amlodipine was given once daily at 2." | 2.71 | Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for ( Hayashi, M; Ideura, T; Iino, Y; Kawaguchi, Y; Kawamura, T; Kitajima, T; Koyama, A; Kuwahara, M; Shiigai, T; Sugisaki, T; Suzuki, H; Tomino, Y; Uchida, S; Umemura, S; Yamada, K; Yamazaki, T, 2003) |
| "Hypertension is a leading cause of end-stage renal disease (ESRD) in the United States, with no known treatment to prevent progressive declines leading to ESRD." | 2.70 | Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. ( Agodoa, LY; Appel, LJ; Bakris, G; Charleston, J; Cheek, D; Douglas-Baltimore, JG; Gassman, J; Glassock, R; Greene, T; Hebert, L; Jamerson, K; Lewis, J; Middleton, JP; Phillips, RA; Rostand, SG; Toto, RD; Wright, JT, 2002) |
| "Although proteinuria has been considered a surrogate of renal disease progression, further studies will be necessary to confirm this hypothesis in ADPKD, because after 5 years, no differences in renal function were observed between the enalapril and amlodipine groups." | 2.69 | Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. ( Brosnahan, GM; Chapman, AB; Ecder, T; Edelstein, CL; Johnson, AM; Schrier, RW, 2000) |
| "Of the hypertensive NIDDM patients attending the outpatient's clinic of the internal medicine departments of the University of Padova and Sassari, 44 participated in the present study." | 2.68 | Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. ( Brocco, E; Carraro, A; Cernigoi, AM; Fioretto, P; Fresu, P; Frigato, F; Maioli, M; Muollo, B; Nosadini, R; Tonolo, G; Velussi, M; Zolli, M, 1996) |
| "Approximately 40% of the patients with type 2 diabetes will develop diabetic kidney disease." | 2.42 | Treatment of diabetic nephropathy with angiotensin II receptor antagonist. ( Lewis, EJ; Lewis, JB, 2003) |
| "In patients with established Type 2 diabetic nephropathy and CKD Stages 1-5, irbesartan safely and significantly slowed the rate of ΔeGFR decline (-2." | 1.38 | Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. ( Bain, SC; Bilous, RW; Evans, M; Hogan, S, 2012) |
| "Compared with the placebo-treated group, proteinuria was significantly lower in the irbesartan- and efonidipine-treated groups, but not in the amlodipine-treated group." | 1.36 | Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats. ( Jin, D; Miyazaki, M; Sakonjo, H; Takai, S, 2010) |
| "Proteinuria was reduced with both drugs." | 1.31 | Influence of the timing of initiating antihypertensive therapy in hypertensive rats with renal failure. ( Kanno, Y; Okada, H; Saruta, T; Suzuki, H; Takenaka, T, 2000) |
| "Both in CHF (congestive heart failure) and CRI (chronic renal insufficiency), blood pressure reduction is beneficial for preservation of cardiac and renal function." | 1.31 | Intensive blood pressure reduction is beneficial in patients with impaired cardiac function coexisting with chronic renal insufficiency. ( Ikeda, N; Kanno, Y; Moriwaki, K; Nakamoto, H; Okada, H; Sugahara, S; Suzuki, H, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (14.93) | 18.2507 |
| 2000's | 38 (56.72) | 29.6817 |
| 2010's | 19 (28.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kwon, YJ | 1 |
| Suh, GH | 1 |
| Kang, SS | 1 |
| Kim, HJ | 1 |
| Tsuchida, T | 1 |
| Yano, H | 1 |
| Raita, Y | 1 |
| Kinjo, M | 1 |
| Yilmaz, MI | 1 |
| Sonmez, A | 1 |
| Saglam, M | 1 |
| Kurt, YG | 1 |
| Unal, HU | 1 |
| Karaman, M | 1 |
| Gok, M | 1 |
| Cetinkaya, H | 1 |
| Eyileten, T | 1 |
| Oguz, Y | 1 |
| Vural, A | 1 |
| Mallamaci, F | 1 |
| Zoccali, C | 1 |
| Ishimitsu, T | 2 |
| Fukuda, H | 1 |
| Uchida, M | 1 |
| Ishibashi, K | 1 |
| Sato, F | 1 |
| Nukui, K | 1 |
| Nagao, M | 1 |
| Gjorgjievska, K | 1 |
| Zafirov, D | 1 |
| Jurhar-Pavlova, M | 1 |
| Cekovska, S | 1 |
| Atanasovska, E | 1 |
| Pavlovska, K | 1 |
| Zendelovska, D | 1 |
| Moes, AD | 1 |
| Hesselink, DA | 1 |
| van den Meiracker, AH | 1 |
| Zietse, R | 1 |
| Hoorn, EJ | 1 |
| Toto, RD | 4 |
| Tian, M | 1 |
| Fakouhi, K | 1 |
| Champion, A | 1 |
| Bacher, P | 1 |
| Guo, LL | 1 |
| Pan, Y | 2 |
| Jin, HM | 2 |
| Abe, M | 1 |
| Okada, K | 1 |
| Maruyama, T | 1 |
| Maruyama, N | 1 |
| Matsumoto, K | 1 |
| Du, J | 1 |
| Fan, YY | 2 |
| Hitomi, H | 2 |
| Kiyomoto, H | 1 |
| Kimura, S | 1 |
| Kong, CZ | 1 |
| Noma, T | 2 |
| Kohno, M | 2 |
| Nishiyama, A | 2 |
| Nakano, D | 2 |
| Li, J | 2 |
| Li, QX | 2 |
| Xie, XF | 1 |
| Ao, Y | 1 |
| Tie, CR | 1 |
| Song, RJ | 1 |
| Webb, NJ | 2 |
| Lam, C | 2 |
| Loeys, T | 1 |
| Shahinfar, S | 2 |
| Strehlau, J | 2 |
| Wells, TG | 2 |
| Santoro, E | 1 |
| Manas, D | 1 |
| Gleim, GW | 2 |
| Nakamura, T | 3 |
| Sato, E | 2 |
| Fujiwara, N | 2 |
| Kawagoe, Y | 3 |
| Ueda, Y | 3 |
| Sugaya, T | 2 |
| Yamagishi, S | 2 |
| Yamada, S | 1 |
| Koide, H | 3 |
| Ohsaki, H | 1 |
| Kobori, H | 1 |
| Suwarni, D | 1 |
| Ohashi, N | 1 |
| Asanuma, K | 1 |
| Tomino, Y | 3 |
| Fujita, T | 3 |
| Takai, S | 1 |
| Jin, D | 1 |
| Sakonjo, H | 1 |
| Miyazaki, M | 1 |
| Liang, W | 1 |
| Chen, C | 1 |
| Shi, J | 1 |
| Ren, Z | 1 |
| Hu, F | 1 |
| van Goor, H | 1 |
| Singhal, PC | 1 |
| Ding, G | 1 |
| Miwa, Y | 1 |
| Tsuchihashi, T | 1 |
| Ohta, Y | 1 |
| Tominaga, M | 1 |
| Kawano, Y | 1 |
| Sasaguri, T | 1 |
| Ueno, M | 1 |
| Matsuoka, H | 2 |
| Suzuki, J | 1 |
| Otsuka, F | 1 |
| Inagaki, K | 1 |
| Tanabe, K | 1 |
| Tsukamoto, N | 1 |
| Miyoshi, T | 1 |
| Nakamura, E | 1 |
| Ogura, T | 1 |
| Kumagai, I | 1 |
| Makino, H | 1 |
| Toba, H | 1 |
| Yoshida, M | 1 |
| Tojo, C | 1 |
| Nakano, A | 1 |
| Oshima, Y | 1 |
| Kojima, Y | 1 |
| Noda, K | 1 |
| Wang, J | 1 |
| Kobara, M | 1 |
| Nakata, T | 1 |
| Le Bailly De Tilleghem, C | 1 |
| Takeuchi, M | 1 |
| Evans, M | 1 |
| Bain, SC | 1 |
| Hogan, S | 1 |
| Bilous, RW | 1 |
| Aritomi, S | 1 |
| Niinuma, K | 1 |
| Ogawa, T | 1 |
| Konda, T | 1 |
| Nitta, K | 1 |
| Bajnok, L | 1 |
| Wright, JT | 2 |
| Bakris, G | 1 |
| Greene, T | 3 |
| Agodoa, LY | 3 |
| Appel, LJ | 1 |
| Charleston, J | 2 |
| Cheek, D | 3 |
| Douglas-Baltimore, JG | 1 |
| Gassman, J | 2 |
| Glassock, R | 1 |
| Hebert, L | 2 |
| Jamerson, K | 2 |
| Lewis, J | 1 |
| Phillips, RA | 2 |
| Middleton, JP | 1 |
| Rostand, SG | 1 |
| Bernadet-Monrozies, P | 1 |
| Rostaing, L | 1 |
| Kamar, N | 1 |
| Durand, D | 1 |
| Kuriyama, S | 1 |
| Tomonari, H | 1 |
| Tokudome, G | 1 |
| Horiguchi, M | 1 |
| Hayashi, H | 1 |
| Kobayashi, H | 1 |
| Ishikawa, M | 1 |
| Hosoya, T | 2 |
| Kanno, Y | 5 |
| Okada, H | 5 |
| Moriwaki, K | 2 |
| Nagao, S | 1 |
| Takahashi, H | 1 |
| Suzuki, H | 7 |
| Park, HC | 1 |
| Xu, ZG | 1 |
| Choi, S | 1 |
| Goo, YS | 1 |
| Kang, SW | 1 |
| Choi, KH | 1 |
| Ha, SK | 1 |
| Lee, HY | 1 |
| Han, DS | 1 |
| Boero, R | 1 |
| Rollino, C | 1 |
| Massara, C | 1 |
| Berto, IM | 1 |
| Perosa, P | 1 |
| Vagelli, G | 1 |
| Lanfranco, G | 1 |
| Quarello, F | 1 |
| Praga, M | 2 |
| Andrade, CF | 1 |
| Luño, J | 2 |
| Arias, M | 2 |
| Poveda, R | 2 |
| Mora, J | 1 |
| Prat, MV | 1 |
| Rivera, F | 2 |
| Galceran, JM | 2 |
| Ara, JM | 1 |
| Aguirre, R | 1 |
| Bernis, C | 1 |
| Marín, R | 2 |
| Campistol, JM | 2 |
| Iino, Y | 2 |
| Hayashi, M | 2 |
| Kawamura, T | 2 |
| Shiigai, T | 2 |
| Yamada, K | 2 |
| Kitajima, T | 2 |
| Ideura, T | 3 |
| Koyama, A | 2 |
| Sugisaki, T | 2 |
| Umemura, S | 2 |
| Kawaguchi, Y | 1 |
| Uchida, S | 2 |
| Kuwahara, M | 2 |
| Yamazaki, T | 2 |
| Lewis, EJ | 3 |
| Lewis, JB | 3 |
| Ruilope, LM | 1 |
| Segura, J | 1 |
| Ghosh, AK | 1 |
| Ghosh, K | 1 |
| Kawaguchii, Y | 1 |
| Kojima, S | 1 |
| Shida, M | 1 |
| Yokoyama, H | 1 |
| Homma, K | 1 |
| Hayashi, K | 2 |
| Kanda, T | 1 |
| Yoshioka, K | 1 |
| Takamatsu, I | 1 |
| Tatematsu, S | 1 |
| Kumagai, H | 2 |
| Wakino, S | 1 |
| Saruta, T | 4 |
| Nutahara, K | 1 |
| Higashihara, E | 1 |
| Horie, S | 1 |
| Kamura, K | 1 |
| Tsuchiya, K | 1 |
| Mochizuki, T | 1 |
| Nakayama, T | 1 |
| Yamamoto, N | 1 |
| Higaki, Y | 1 |
| Shimizu, T | 1 |
| Atkins, RC | 1 |
| Briganti, EM | 1 |
| Hunsicker, LG | 2 |
| Braden, G | 1 |
| Champion de Crespigny, PJ | 1 |
| DeFerrari, G | 1 |
| Drury, P | 1 |
| Locatelli, F | 1 |
| Wiegmann, TB | 1 |
| Contreras, G | 1 |
| Junco, G | 1 |
| Dowie, D | 2 |
| Lash, J | 2 |
| Lipkowitz, M | 2 |
| Miller, ER | 2 |
| Ojo, A | 2 |
| Sika, M | 1 |
| Wilkening, B | 1 |
| Wei, L | 1 |
| Tan, J | 1 |
| Coto, E | 1 |
| Alvarez, V | 1 |
| Fernández Andrade, C | 1 |
| Vallés, M | 1 |
| Onami, T | 1 |
| Takimoto, C | 1 |
| Iigaya, K | 1 |
| Liu, LL | 1 |
| Xia, L | 1 |
| Shao, L | 1 |
| Suzuki, T | 1 |
| Inoue, T | 1 |
| Node, K | 1 |
| Kameda, T | 1 |
| Akashiba, A | 1 |
| Takahashi, T | 1 |
| Ohta, S | 1 |
| Yoshii, M | 1 |
| Minami, J | 1 |
| Ono, H | 1 |
| Numabe, A | 1 |
| Ando, K | 1 |
| Nishimura, H | 1 |
| Yasuda, G | 1 |
| Isshiki, M | 1 |
| Takahashi, K | 1 |
| Ohishi, M | 1 |
| Takagi, T | 1 |
| Ito, N | 1 |
| Terai, M | 1 |
| Tatara, Y | 1 |
| Hayashi, N | 1 |
| Shiota, A | 1 |
| Katsuya, T | 1 |
| Rakugi, H | 1 |
| Ogihara, T | 1 |
| August, P | 1 |
| Lenz, T | 1 |
| Laragh, JH | 1 |
| Velussi, M | 1 |
| Brocco, E | 1 |
| Frigato, F | 1 |
| Zolli, M | 1 |
| Muollo, B | 1 |
| Maioli, M | 1 |
| Carraro, A | 1 |
| Tonolo, G | 1 |
| Fresu, P | 1 |
| Cernigoi, AM | 1 |
| Fioretto, P | 1 |
| Nosadini, R | 1 |
| Dworkin, LD | 1 |
| Tolbert, E | 1 |
| Recht, PA | 1 |
| Hersch, JC | 1 |
| Feiner, H | 1 |
| Levin, RI | 1 |
| Ikenaga, H | 1 |
| Ishii, N | 1 |
| Itoh, H | 1 |
| Hanson, B | 1 |
| D'Hondt, A | 1 |
| Depierreux, M | 1 |
| Lustman, F | 1 |
| Bakris, GL | 2 |
| Griffin, KA | 1 |
| Picken, MM | 1 |
| Bidani, AK | 1 |
| Janssen, JJ | 1 |
| Gans, RO | 1 |
| van der Meulen, J | 1 |
| Pijpers, R | 1 |
| ter Wee, PM | 1 |
| Holdaas, H | 1 |
| Hartmann, A | 1 |
| Berg, KJ | 1 |
| Lund, K | 1 |
| Fauchald, P | 1 |
| Ecder, T | 1 |
| Chapman, AB | 1 |
| Brosnahan, GM | 1 |
| Edelstein, CL | 1 |
| Johnson, AM | 1 |
| Schrier, RW | 1 |
| Atarashi, K | 1 |
| Takagi, M | 1 |
| Minami, M | 1 |
| Ishiyama, A | 1 |
| Takenaka, T | 1 |
| Satomura, A | 1 |
| Hidaka, M | 1 |
| Ohsawa, I | 1 |
| Endo, M | 1 |
| Ohi, H | 1 |
| Appel, L | 1 |
| Beck, G | 1 |
| Bourgoignie, J | 1 |
| Briggs, JP | 1 |
| Cleveland, W | 1 |
| Douglas, JG | 1 |
| Douglas, M | 1 |
| Faulkner, M | 1 |
| Gabriel, A | 1 |
| Hall, Y | 1 |
| Hiremath, L | 1 |
| Johnson, CJ | 1 |
| Kopple, J | 1 |
| Kusek, J | 1 |
| Lea, J | 1 |
| Massry, S | 1 |
| Middleton, J | 1 |
| Norris, K | 1 |
| O'Connor, D | 1 |
| Pogue, V | 1 |
| Rahman, M | 1 |
| Randall, OS | 1 |
| Rostand, S | 1 |
| Schulman, G | 1 |
| Smith, W | 1 |
| Thornley-Brown, D | 1 |
| Tisher, CC | 1 |
| Xu, S | 1 |
| Rodby, RA | 1 |
| Baylis, C | 1 |
| Qiu, C | 1 |
| Engels, K | 1 |
| Ikeda, N | 1 |
| Sugahara, S | 1 |
| Nakamoto, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT01738945] | Phase 4 | 32 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus[NCT02644395] | Phase 3 | 49 participants (Actual) | Interventional | 2013-01-18 | Completed | ||
| Pilot Study to Assess Blockade of Calcium Channels and Sodium Chloride Cotransporters for Physiologic Abnormalities in Liver Transplant Associated Hypertension[NCT05275907] | Phase 4 | 0 participants (Actual) | Interventional | 2022-07-12 | Withdrawn (stopped due to Screened participants did not meet inclusion criteria prior to study completion date) | ||
| A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension[NCT00568178] | Phase 3 | 306 participants (Actual) | Interventional | 2007-06-01 | Completed | ||
| Medication Adherence Given Individual SystemCHANGE(TM) in Advancing Nephropathy (MAGICIAN) Pilot Study[NCT04616612] | 150 participants (Anticipated) | Interventional | 2021-12-15 | Recruiting | |||
| African American Study of Kidney Disease and Hypertension[NCT04364139] | Phase 3 | 1,094 participants (Actual) | Interventional | 1995-02-01 | Completed | ||
| Effect of Renin-angiotensin-system (RAS) Blocker Drugs on Chronic Kidney Disease (CKD) Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)[NCT03195023] | Phase 4 | 106 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| A Randomized, Parallel, Double Blind Study of Losartan Versus Amlodipine in Patients With Mild to Moderate Hypertension and Chronic Nondiabetic Proteinuric Nephropathy: Evaluation of the Effect on Proteinuria and on the Plasmatic Levels of Growth Factors [NCT00140985] | Phase 4 | 97 participants (Actual) | Interventional | 2000-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00568178)
Timeframe: Baseline and Week 12
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan-Hypertensive Participants | -3.8 |
| Amlodipine-Hypertensive Participants | 0.8 |
(NCT00568178)
Timeframe: Baseline and Week 12
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan-Hypertensive Participants | -5.5 |
| Amlodipine-Hypertensive Participants | -0.1 |
"Change in urinary protein excretion, determined as urinary Pr/Cr ratio compared to baseline*, after approximately twelve weeks of treatment.~Baseline is defined as values obtained at Visit 3, Week (-1) during the Single Blind Run-in period." (NCT00568178)
Timeframe: Baseline and Week 12
| Intervention | Percent Change in Pr/Cr (Geometric Mean) |
|---|---|
| Losartan | -35.80 |
| Amlodipine/Placebo | 1.37 |
"The outcome measure of glomerular filtration rate was based on mL/min/1.73m^2, as determined by the Schwartz formula:~GFR = _____0.55 x height (cm)_______ divided by serum creatinine (mg/dL)~GFR values were compared to the baseline GFR measure.~[Note: For male participants, ages 13 to 17 years, 0.70 was used as~the multiplier in place of 0.55]~Baseline in regard to the extension is defined as the last value obtained in the double-blind treatment phase." (NCT00568178)
Timeframe: Baseline and Month 36
| Intervention | Change in GFR mL/min1.73m^2 (Least Squares Mean) |
|---|---|
| Losartan Open Label Extension | 3.3 |
| Enalapril Open Label Extension | 7.0 |
"Change in urinary protein excretion, determined as urinary Pr/Cr ratio compared to baseline*, after approximately three years of treatment.~*The baseline for efficacy data in the extension was defined as the last value obtained in the double-blind treatment phase." (NCT00568178)
Timeframe: Baseline and Month 36
| Intervention | Percent Change in Pr/Cr (Geometric Mean) |
|---|---|
| Losartan Open Label Extension | -30.01 |
| Enalapril Open Label Extension | -40.45 |
5 reviews available for amlodipine and Proteinuria
| Article | Year |
|---|---|
[Lessons from the novel renoprotective studies with antihypertensive drugs].
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 2013 |
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2002 |
Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Creatinin | 2003 |
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Topics: Albuminuria; Amlodipine; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Clinical Trial | 2003 |
[Novel actions of calcium channel blockers].
Topics: Amlodipine; Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; Depression; Dihydropyridine | 2006 |
35 trials available for amlodipine and Proteinuria
| Article | Year |
|---|---|
Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diabetes Mellitus, Type | 2014 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Be | 2008 |
Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan.
Topics: Adiponectin; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabe | 2009 |
Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Dihydropyridine | 2009 |
Randomized, double-blind, controlled study of losartan in children with proteinuria.
Topics: Adolescent; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers | 2010 |
Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Amlodipine; Atherosclerosis; Biomarkers; Calcium Channel Blocker | 2010 |
Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors - a multicenter, open, randomized trial using 24-hour urine collection.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Dihydropyridines; Fe | 2010 |
Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial.
Topics: Adolescent; Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Child; Child, Preschool; Dou | 2011 |
Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease.
Topics: Adult; Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive A | 2011 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihy | 2002 |
Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Female; Glomerulonephritis, IGA; Humans; | 2003 |
The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Double- | 2003 |
Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial.
Topics: Adult; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Calcium Channel Blocke | 2003 |
Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; | 2003 |
Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension--a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Female; Humans; Hypertension, Renal; Japan; Kidney Failur | 2004 |
Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases.
Topics: Aged; Amlodipine; Calcium Channel Blockers; Calcium Channels, N-Type; Creatinine; Dihydropyridines; | 2004 |
Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2004 |
Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphe | 2005 |
Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy.
Topics: Adult; Aged; Amlodipine; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nep | 2005 |
Blood pressure control, drug therapy, and kidney disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2005 |
Clinical observation on Breviscapine in treating hypertension patients complicated with micro-albuminuria of renal impairment.
Topics: Adult; Aged; Albuminuria; Amlodipine; Antihypertensive Agents; beta 2-Microglobulin; Blood Pressure; | 2005 |
Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; C-Peptide; Calcium | 2007 |
Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Amlodipine; Antioxidants; Azetidinecarboxylic Acid; Blood Pressu | 2007 |
Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis.
Topics: Adult; Aged; Aldosterone; Amlodipine; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L- | 2007 |
Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; | 2007 |
Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study.
Topics: Aged; Amlodipine; Calcium Channel Blockers; Dihydropyridines; Female; Guideline Adherence; Humans; H | 2007 |
Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pr | 1996 |
Comparison between the effects of amlodipine and lisinopril on proteinuria in nondiabetic renal failure: a double-blind, randomized prospective study.
Topics: Adolescent; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Block | 1998 |
Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy.
Topics: Adult; Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Biomarkers; Blood Pressure; Cross-Ove | 1998 |
Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease.
Topics: Adult; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Ch | 2000 |
Angiotensin-converting enzyme inhibitors improve nephrosis more quickly than calcium antagonists in diabetic patients.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blocker | 2000 |
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2001 |
A clinical trial in type 2 diabetic nephropathy.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Calcium Channel Block | 2001 |
27 other studies available for amlodipine and Proteinuria
| Article | Year |
|---|---|
Successful management of proteinuria and systemic hypertension in a dog with renal cell carcinoma with surgery, telmisartan, and amlodipine.
Topics: Amlodipine; Animals; Antihypertensive Agents; Carcinoma, Renal Cell; Dog Diseases; Dogs; Hypertensio | 2018 |
Nephrotic range proteinuria and metabolic alkalosis in Takayasu arteritis.
Topics: Adolescent; Alkalosis; Amlodipine; Antihypertensive Agents; Female; Glomerulosclerosis, Focal Segmen | 2019 |
The therapeutic advantage of combination antihypertensive drug therapy using amlodipine and irbesartan in hypertensive patients: Analysis of the post-marketing survey data from PARTNER (Practical combination therapy of Amlodin and angiotensin II Receptor
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Blood Pressure | 2015 |
Protective effects of AT1-receptor blocker and CA antagonist combination on renal function in salt loaded spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Body Weight; Calcium C | 2015 |
Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cell Hypoxia | 2009 |
Differential roles of dihydropyridine calcium antagonist nifedipine, nitrendipine and amlodipine on gentamicin-induced renal tubular toxicity in rats.
Topics: Acetylglucosaminidase; Amlodipine; Animals; Apoptosis; bcl-2-Associated X Protein; Blood Urea Nitrog | 2009 |
Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte.
Topics: Amlodipine; Animals; Base Sequence; Blood Glucose; Blood Pressure; Body Weight; Calcium Channel Bloc | 2010 |
Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Pressure; Ca | 2010 |
Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats.
Topics: Albuminuria; Aldosterone; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; | 2011 |
Effects of eplerenone on nephrotic syndrome in a patient with renovascular hypertension.
Topics: Amlodipine; Antihypertensive Agents; Dihydropyridines; Eplerenone; Humans; Hypertension, Renovascula | 2011 |
L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; C | 2011 |
Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Di | 2012 |
Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; B | 2013 |
The effects of antihypertensive agents on the survival rate of polycystic kidney disease in Han:SPRD rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Body Weight; Kidney; Kid | 2002 |
Anti-proteinuric effect of losartan: statistical vs clinical significance.
Topics: Amlodipine; Antihypertensive Agents; Data Interpretation, Statistical; Humans; Losartan; Proteinuria | 2004 |
[Pharmacogenetics of angiotensin system in non diabetic nephropathy].
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel | 2005 |
Differential effects of dihydropyridine calcium antagonists on doxorubicin-induced nephrotoxicity in rats.
Topics: Amlodipine; Animals; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Blood Urea Nitrogen; Calci | 2007 |
Renal protective effects of amlodipine on partially nephrectomized spontaneously hypertensive rats fed a high-salt diet.
Topics: Amlodipine; Animals; Blood Pressure; Body Weight; Hypertension; Kidney; Kidney Diseases; Nephrectomy | 1994 |
Comparative renal hemodynamic effects of lisinopril, verapamil, and amlodipine in patients with chronic renal failure.
Topics: Amlodipine; Antihypertensive Agents; Dipeptides; Hemodynamics; Humans; Kidney Failure, Chronic; Lisi | 1993 |
Effects of amlodipine on glomerular filtration, growth, and injury in experimental hypertension.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Desoxycorticosterone; Glo | 1996 |
Does combined therapy of Ca-channel blocker and angiotensin converting enzyme inhibitor exceed monotherapy in renal protection against hypertensive injury in rats?
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Calcium | 1996 |
Nephrotic syndrome after norfloxacin.
Topics: Aged; Amlodipine; Anti-Infective Agents; Antihypertensive Agents; Clonidine; Creatinine; Diuretics; | 1996 |
Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Blood Pressure; Calcium | 1997 |
Effects of alacepril and amlodipine on the renal injury induced by a high-cholesterol diet in rats.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Calcium | 1999 |
Influence of the timing of initiating antihypertensive therapy in hypertensive rats with renal failure.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressu | 2000 |
Comparison of L-type and mixed L- and T-type calcium channel blockers on kidney injury caused by deoxycorticosterone-salt hypertension in rats.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; C | 2001 |
Intensive blood pressure reduction is beneficial in patients with impaired cardiac function coexisting with chronic renal insufficiency.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Crea | 2002 |